拱东医疗公告，截至本公告披露日，控股股东、实际控制人施慧勇持有1.11亿股，占50.27%；拟于2025 年9月26日至2025年12月24日通过大宗交易减持不超过440.99万股，比例不超过2%。股东台州金驰投资 管理合伙企业（有限合伙）持有1425.8万股，占6.47%；同期拟通过集中竞价减持不超过220.49万股， 比例不超过1%。 ...

Core Viewpoint - Gongdong Medical (605369.SH) announced that its controlling shareholder and actual controller, Shi Huiyong, plans to reduce holdings through block trading, with a maximum of 4.4099 million shares, not exceeding 2% of the total share capital within three months after the announcement [1] Summary by Category - **Shareholder Reduction Plans** - Shi Huiyong intends to reduce holdings by up to 4.4099 million shares through block trading, within three months after the announcement [1] - Jincheng Investment plans to reduce holdings by up to 2.2049 million shares through centralized bidding, not exceeding 1% of the total share capital [1]

人民财讯9月4日电，拱东医疗（605369）9月4日晚间公告，公司控股股东、实控人施慧勇拟通过大宗交 易方式，减持公司股份不超过440.99万股(占公司总股本的2%)；控股股东、实控人之一致行动人金驰投 资拟通过集中竞价交易方式，减持公司股份不超过220.49万股(占公司总股本的1%)。 ...

Core Viewpoint - Gongdong Medical's stock price has decreased by 2.69% to 19.9 yuan, with a current market capitalization of 4.388 billion yuan, ranking 86th in the medical device sector and 3636th in the A-share market [1] Shareholder Changes - As of June 30, 2025, the number of shareholders for Gongdong Medical was 9,870, an increase of 10.79% from March 31, 2025, with an average shareholding of 22,300 shares per account, resulting in an average market value of 424,200 yuan [2][5] Performance Disclosure Highlights - Gongdong Medical's mid-year report for 2025 shows a main revenue of 557 million yuan, a year-on-year increase of 0.58%, while the net profit attributable to shareholders decreased by 47.16% to 50.349 million yuan. The second quarter revenue was 292 million yuan, up 3.78% year-on-year, but the net profit dropped by 54.3% to 22.937 million yuan [3][5] Company Announcements Summary - The third board meeting of Gongdong Medical on August 25, 2025, approved several proposals, including the cancellation of the supervisory board and amendments to the company’s articles of association. A temporary shareholders' meeting is scheduled for September 18, 2025, to discuss these changes, with the supervisory board's responsibilities to be transferred to the audit committee of the board [4][5]

Core Insights - The company Gongdong Medical (605369) reported a slight increase in total revenue for the first half of 2025, reaching 557 million yuan, a year-on-year increase of 0.58%, while the net profit attributable to shareholders significantly decreased by 47.16% to 50.35 million yuan [1] Financial Performance - Total revenue for Q2 2025 was 292 million yuan, up 3.78% year-on-year, but net profit for the same quarter fell by 54.3% to 22.94 million yuan [1] - The gross margin decreased to 31.31%, down 5.75% year-on-year, and the net margin dropped to 9.04%, a decline of 47.5% [1] - The total of selling, administrative, and financial expenses (three expenses) reached 76.82 million yuan, accounting for 13.79% of total revenue, which is an increase of 48.41% year-on-year [1] - Earnings per share fell to 0.23 yuan, a decrease of 46.51% compared to the previous year [1] Balance Sheet Changes - Cash and cash equivalents increased by 21.81% to 597 million yuan, attributed to the recovery of previous financial products and new bank loans [1] - Accounts receivable rose by 19.97% to 316 million yuan due to the consolidation of Jindongsheng [2] - Interest-bearing liabilities surged by 2984.90% to 194 million yuan, primarily due to new bank borrowings [1][6] Expense Analysis - Selling expenses increased by 8.52% due to the consolidation of Jindongsheng's sales expenses [11] - Management expenses rose by 26.08%, driven by increased salaries and intermediary service costs [11] - Financial expenses saw a significant increase of 89.27%, influenced by decreased interest income and foreign exchange losses [11] Cash Flow Insights - Net cash flow from operating activities increased by 11.07%, supported by new export tax rebates [11] - Net cash flow from investing activities surged by 565.68%, due to the recovery of financial products and payments related to the acquisition of Jindongsheng [11] - Net cash flow from financing activities skyrocketed by 3503.39%, primarily due to new bank loans [11] Overall Assessment - The company's return on invested capital (ROIC) was 8.76%, indicating average capital returns, with a historical median ROIC of 22.72% since its listing [11] - The company maintains a healthy cash position, but the accounts receivable to profit ratio has reached 184.16%, suggesting potential concerns in receivables management [12]

Core Insights - Gongdong Medical (605369.SH) released its semi-annual report for 2025, indicating that as of August 25, 2025, four institutional investors disclosed holdings in Gongdong Medical A-shares, totaling 19.0232 million shares, which represents 8.63% of the total share capital [1] Institutional Holdings - The institutional investors include Taizhou Jincheng Investment Management Partnership (Limited Partnership), Guotai Jiatai Stock Special Pension Product - China Merchants Bank Co., Ltd., Zhejiang Gongdong Medical Devices Co., Ltd. - First Employee Stock Ownership Plan, and Guotai Fund Management Co., Ltd. - Social Security Fund 2103 Combination [1] - The total institutional holding percentage decreased by 0.59 percentage points compared to the previous quarter [1] Public Fund Disclosures - In this period, two public funds were disclosed that had not been reported in the previous quarter, including ICBC Medical Health Stock and Yuanxin Yongfeng Xingyuan A [1] Social Security Fund - One new social security fund disclosed its holdings in Gongdong Medical, specifically Guotai Fund Management Co., Ltd. - Social Security Fund 2103 Combination [1]

浙江拱东医疗器械股份有限公司 2025 年半年度报告 公司代码：605369 公司简称：拱东医疗 浙江拱东医疗器械股份有限公司 浙江拱东医疗器械股份有限公司 2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人施慧勇、主管会计工作负责人朱勇及会计机构负责人（会计主管人员）尤志仁 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的经营计划、发展战略、未来计划等前瞻性陈述不构成公司对投资者的实质 承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、预测与承诺之间 的差异。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告 ...

Core Viewpoint - Zhejiang Gongdong Medical Devices Co., Ltd. reported a slight increase in revenue but a significant decline in profit for the first half of 2025, indicating potential challenges in operational efficiency and profitability [1]. Financial Summary - Total assets at the end of the reporting period reached approximately 2.12 billion RMB, an increase of 8.73% compared to the end of the previous year [1]. - Operating revenue for the period was approximately 556.92 million RMB, reflecting a modest increase of 0.58% year-on-year [1]. - Total profit for the period was approximately 55.86 million RMB, showing a substantial decrease of 47.86% compared to the same period last year [1]. - Net profit attributable to shareholders was significantly lower, with a basic earnings per share of 0.23 RMB, down 46.51% from 0.43 RMB in the previous year [1]. - The weighted average return on net assets decreased to 2.91%, down 2.76 percentage points from the previous year [1]. Shareholder Information - The largest shareholder, Shi Huiyong, holds 50.27% of the shares, followed by Shi Yibei with 7.47% [2]. - Other notable shareholders include Taizhou Jinch Investment Management Partnership and several individuals with smaller stakes [2]. - There are noted relationships among major shareholders, indicating potential unified actions in decision-making [3].

Group 1 - The third meeting of the supervisory board of Zhejiang Gongdong Medical Instrument Co., Ltd. was held on August 25, 2025, with all three supervisors present, confirming the legality and validity of the meeting [1][2] - The supervisory board approved the proposal regarding the company's 2025 semi-annual report and its summary, with a unanimous vote of 3 in favor [1][2] - The supervisory board also approved the proposal to cancel the supervisory board and amend the company's articles of association, which will require further approval from the shareholders' meeting [2]

Meeting Information - The first extraordinary general meeting of shareholders for 2025 will be held on September 18, 2025, at 14:00 [1] - The meeting will take place in the conference room on the third floor of Zhejiang Gongdong Medical Instrument Co., Ltd. [1] - Shareholders can vote through the Shanghai Stock Exchange's online voting system from 9:15 to 15:00 on the day of the meeting [1][3] Voting Procedures - Shareholders can participate in voting via both on-site and online methods [3][4] - For online voting, shareholders must complete identity verification if logging in for the first time [3] - Shareholders with multiple accounts can vote through any of their accounts, but the first voting result will be considered valid [4] Attendance and Registration - Shareholders registered with China Securities Depository and Clearing Corporation Limited by the close of trading on September 10, 2025, are eligible to attend [4] - Shareholders can appoint representatives to attend the meeting, who must present valid identification and authorization documents [5][6] Proxy Voting - Proxy voting requires a written authorization letter, which must include specific details such as the proxy's name and voting instructions [5][8] - The proxy must present the authorization letter and identification at the meeting [5][6] Contact Information - The company has provided contact details for inquiries regarding the meeting [6]